bumetanide has been researched along with Disease Exacerbation in 5 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Our data demonstrate an anticonvulsant effect of bumetanide on KA-induced seizures in adult mice, suggesting a role for chloride plasticity in seizure progression." | 7.83 | Bumetanide reduces seizure progression and the development of pharmacoresistant status epilepticus. ( Maguire, J; Sivakumaran, S, 2016) |
| "Our data demonstrate an anticonvulsant effect of bumetanide on KA-induced seizures in adult mice, suggesting a role for chloride plasticity in seizure progression." | 3.83 | Bumetanide reduces seizure progression and the development of pharmacoresistant status epilepticus. ( Maguire, J; Sivakumaran, S, 2016) |
| "Autism spectrum disorder is defined by two core symptoms: a deficit in social communication and the presence of repetitive behaviors and/or restricted interests." | 2.58 | Social Skills Deficits in Autism Spectrum Disorder: Potential Biological Origins and Progress in Developing Therapeutic Agents. ( Frye, RE, 2018) |
| "Treatment with bumetanide, an NKCC inhibitor, had no effect on mechanical hypersensitivity seen in mice with EAE even though it reversed the changes in the levels of NKCC1 and KCC2." | 1.46 | The chloride co-transporters, NKCC1 and KCC2, in experimental autoimmune encephalomyelitis (EAE). ( Kerr, B; Tenorio, G; Yousuf, MS; Zubkow, K, 2017) |
| "Medical treatment of idiopathic intracranial hypertension is often ineffective." | 1.37 | Resolution of headache and papilledema in idiopathic intracranial hypertension associated with inhibition of Na+-K+-2Cl- cotransport. ( Kahle, KT; Staley, KJ; Walcott, BP, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Frye, RE | 1 |
| Mesuret, G | 1 |
| Engel, T | 1 |
| Hessel, EV | 1 |
| Sanz-Rodriguez, A | 1 |
| Jimenez-Pacheco, A | 1 |
| Miras-Portugal, MT | 1 |
| Diaz-Hernandez, M | 1 |
| Henshall, DC | 1 |
| Sivakumaran, S | 1 |
| Maguire, J | 1 |
| Yousuf, MS | 1 |
| Zubkow, K | 1 |
| Tenorio, G | 1 |
| Kerr, B | 1 |
| Kahle, KT | 1 |
| Walcott, BP | 1 |
| Staley, KJ | 1 |
1 review available for bumetanide and Disease Exacerbation
| Article | Year |
|---|---|
Social Skills Deficits in Autism Spectrum Disorder: Potential Biological Origins and Progress in Developing Therapeutic Agents.
Topics: Autism Spectrum Disorder; Bumetanide; Disease Progression; Fecal Microbiota Transplantation; Humans; | 2018 |
4 other studies available for bumetanide and Disease Exacerbation
| Article | Year |
|---|---|
P2X7 receptor inhibition interrupts the progression of seizures in immature rats and reduces hippocampal damage.
Topics: Amygdala; Animals; Animals, Newborn; Bumetanide; Cell Death; Disease Models, Animal; Disease Progres | 2014 |
Bumetanide reduces seizure progression and the development of pharmacoresistant status epilepticus.
Topics: Animals; Anticonvulsants; Brain; Bumetanide; Diazepam; Disease Progression; Drug Resistant Epilepsy; | 2016 |
The chloride co-transporters, NKCC1 and KCC2, in experimental autoimmune encephalomyelitis (EAE).
Topics: Animals; Bumetanide; Disease Progression; Encephalomyelitis, Autoimmune, Experimental; Female; Gangl | 2017 |
Resolution of headache and papilledema in idiopathic intracranial hypertension associated with inhibition of Na+-K+-2Cl- cotransport.
Topics: Adolescent; Bumetanide; Disease Progression; Female; Headache; Humans; Papilledema; Pseudotumor Cere | 2011 |